Novo Nordisk slips despite growing Wegovy, Ozempic sales
slipped 2% in premarket trading after it reported growing sales of its blockbuster GLP-1 drugs but reiterated that knockoffs were eating at its weight-loss business. Quarterly sales of its weight-loss...
CRISPR shares fall after gene-editing company’s Q2 falls short of estimates
Shares of slid 4% Monday after the Swiss biotech missed Wall Street’s Q2 expectations after the bell Monday, despite growing excitement around its flagship gene-editing therapy. CRISPR posted a wide...
Pfizer rises after earnings beat, boost to full-year profit outlook
rose in premarket trading after it reported earnings results that beat Wall Street’s expectations and raised its full-year outlook. The company reported adjusted earnings per share of $0.78, compared ...
All eyes are on Hims’ weight-loss biz ahead of Monday earnings
is set to report earnings after the bell on Monday, giving investors a peek at how its weight-loss business has held up amid a storm of controversy. The company’s stock has been on a roller coaster th...
Moderna slips after cutting revenue guidance
slipped after it reported Q2 results that beat Wall Street estimates but lowered its revenue guidance for the year. The vaccine maker reported an adjusted loss per share of $2.13, better than the $2.9...
Drugmakers slip after Trump letter asks them to slash prices
Several drugmakers are dipping after President Trump sent a letter to the CEOs of 17 large pharma companies demanding they cut prices for US patients within the next 60 days. The companies that receiv...
Eli Lilly’s diabetes and weight-loss drug is as effective for cardio conditions as its older heart-health medication
blockbuster diabetes and weight-loss drug, Mounjaro, was just as effective at preventing heart attacks and strokes as its older diabetes and cardiovascular treatment, Trulicity, the drugmaker announce...
The rise and fall of Novo Nordisk
Last July, , the drugmaker that brought us Ozempic and Wegovy, was sitting pretty as Europe’s most valuable company — and, with a margin of more than $200 billion between it and storied luxury house L...
Biotechs rally on Vinay Prasad’s exit from FDA
Some biotechs are rallying after it was reported by Stat News and others that Vinay Prasad, a top official at the US Food and Drug Administration, abruptly left the regulator. Prasad’s sudden departur...
Sarepta jumps after FDA allows gene therapy for younger patients
rose more than 20% on Tuesday morning after the Food and Drug Administration said it was clearing the way for the drugmaker to resume shipments of its gene therapy for Duchenne muscular dystrophy to s...
Merck slips despite earnings beat, says it will cut $3 billion in costs
fell 4% in premarket trading Tuesday despite reporting earnings results that beat Wall Street’s expectations. The company reported adjusted earnings per share of $2.13, compared to the $2.02 analysts ...
Novo Nordisk slides after slashing outlook, citing competition from compounded weight-loss drugs
is down more than 15% in premarket trading after the drugmaker behind Ozempic and Wegovy cut its annual sales and profit outlook . The company said the new outlook is driven by lower expectations for...
Celcuity rockets after positive trial results on breast cancer combo treatment
rose more than 200% in early trading after it reported positive results in late-stage trials for its breast cancer combination treatment. The trial studied how Celcuity’s gedatolisib worked alongside ...
Lilly cuts partnership with Noom in latest salvo in war on compounded GLP-1s
has terminated its partnership with Noom after the telehealth platform continued to sell knock-off versions of blockbuster GLP-1 drugs. Lilly's pharmacy provider "has notified Noom that it is terminat...
More than 80 lawmakers tell the FDA to crack down on compounding
A bipartisan group of more than 80 lawmakers sent a letter to the Food and Drug Administration on Friday asking the regulator to crack down on companies selling knockoff weight-loss drugs made by comp...
Sarepta falls after it fails to get EU approval
fell more than 10% in early trading after its gene therapy Elevidys failed to get approval from European regulators. The European Medicines Agency recommended against Elevidys for children with Duchen...
West Pharmaceutical rockets on surging GLP-1 demand
, a company that sells a tiny rubber component of GLP-1 pens, is up more than 20% after it reported earnings that crushed Wall Street estimates thanks to soaring demand for the weight-loss drugs. The...
Tiny biotech Abivax shoots up 500% on positive trial results
French biotech is up nearly 500% in premarket trading after it announced that late-stage trials for its treatment for ulcerative colitis showed promise. The company, which has a market capitalization...
IQVIA leads S&P 500 on strong Q2 earnings, better-than-expected guidance
is leading the S&P 500 in early trading after the provider of clinical research services to the pharmaceutical industry posted stronger-than-expected Q2 earnings and offered full-year sales guidance t...
Medpace rockets on earnings beat, guidance raise
, a clinical trials company, rose nearly 60% in early trading after it reported second-quarter earnings that crushed analysts’ estimates. The company reported earnings per share of $3.10, compared to...